Route of Feeding as a Proxy for Dysphagia After Stroke and the Effect of Transdermal Glyceryl Trinitrate: Data from the Efficacy of Nitric Oxide in Stroke Randomised Controlled Trial

Dysphagia (difficulty in swallowing) is a common complication after stroke affecting up to 65% of patients, many of whom are asymptomatic [1] or have symptoms that are not thought to be related to swallowing problems. Although many patients recover swallowing spontaneously, 11–50% still have dysphagia at 6 months [2, 3]; conversely, a significant proportion of patients are able to swallow safely within 1–2 weeks [1, 3]. Post-stroke dysphagia (PSD) is associated with a poor outcome for multiple reasons: first, it is a manifestation of severe stroke and therefore is associated with increased death, dependency, disability, impairment and institutionalisation; [4] second, it causes aspiration of foods, liquids and oral secretions and therefore pneumonia [5‐7], which in itself leads to death; [6] and third, poor recognition and management leads to dehydration and malnutrition. In the acute phase, the presence of dysphagia leads to changes in the feeding of patients from oral routes to the use of enteral feeding tubes or parenteral fluids.

Although multiple advances have been made in the very early management of stroke (e.g. with thrombolysis, aspirin, mechanical thrombectomy and hemicraniectomy) and secondary prevention (antithrombotics, blood pressure lowering, lipid lowering, carotid endarterectomy), PSD remains a neglected research area and its optimal management, including treatment, have yet to be defined. Nevertheless, stroke guidelines recommend assessment of swallowing within 24 h and patients with an unsafe swallow are recommended to be nil by mouth; these recommendations constitute a key performance indicator in many stroke services. A number of trials have investigated the treatment of dysphagia, including acupuncture, behavioural therapy, physical stimulation, neuromuscular electrical stimulation and pharyngeal electrical stimulation [8‐11], and several have given encouraging results [12]. In respect of drug treatment, a small pilot randomised trial suggested that nifedipine (a calcium channel blocker that relaxes oesophageal smooth muscle) might improve swallowing, and metoclopramide (a dopamine D2-receptor antagonist with antiemetic and gastric prokinetic activity) might reduce the incidence of pneumonia [13, 14]. Conversely, lisinopril (an angiotensin converting enzyme inhibitor) failed to prevent pneumonia [15].

Here we describe the natural history and outcomes of patients with feeding problems in the acute phase of stroke using data from the large ‘Efficacy of Nitric Oxide in Stroke’ (ENOS) trial [16‐19]. We also report the effect of transdermal glyceryl trinitrate (GTN, a nitric oxide (NO) donor that relaxes smooth muscle) hypothesising that it might improve the oesophageal phase of swallowing and therefore return patients to oral feeding and a normal diet [17]. Of relevance, loss of a1ß1 soluble guanylate cyclase, the major NO receptor, leads to moyamoya and achalasia [20], the latter demonstrating the potential relationship between NO and swallowing. Since GTN might improve functional outcome if administered very early (<6 h), as seen in the ENOS and RIGHT trials [19, 21, 22], we have also assessed its effect on feeding route in this subgroup of patients.

These pre-specified [17] secondary exploratory analyses of the ENOS trial confirm earlier data that swallowing problems, assessed here using the surrogate of route of feeding, are common immediately after stroke. Feeding route improved over the first week, and was associated with a poor outcome apparent as increased death, dependency, disability, impairment, institutionalisation and pneumonia. Although GTN did not alter feeding route overall, patients randomised to GTN within 6 h of ictus were less likely to require enteral feeding or parenteral fluids.

The observation that post-stroke swallowing problems are common supports earlier studies [4]. Although many patients improved their feeding route over the first week, some did not and a minority worsened, as reported by others [1‐3]. Factors associated with increased death and dependency included patient characteristics (increased age, female sex), medical history (more hypertension) and clinical presentation (more cortical syndromes and higher stroke severity and blood pressure), as published previously [4]. Further, dysphagia causes aspiration of foods, liquids and oral secretions and therefore pneumonia [5‐7] and death [6], these observations also being seen here.

GTN, if given within 6 h of stroke, improved feeding route at day 7. Although this finding could be due to chance, GTN was associated with improved functional outcome when given hyper-acutely in ENOS [19, 21] and ultra-acutely in the RIGHT pre-hospital trial [22]. This raises the possibility that the improvement in dysphagia (and dependency) results from a reduction in stroke damage due, perhaps, to improved perfusion, blood pressure lowering and/or neuroprotection. In this respect, feeding route is likely to be a biomarker for stroke recovery reflecting a change in phenotype from severe stroke (with swallowing impairment) to a less severe level of stroke and swallowing impairment. Nitric oxide donors also improve exercise tolerance [24] and so might reduce tiring during mastication and swallowing. GTN might also have improved swallowing though relaxing oesophageal smooth muscle thereby improving the oesophageal phase of swallowing, as seen potentially in a small trial of nifedipine [13]. However, such a mechanism would not be expected to be time-dependent and GTN should therefore have improved feeding route irrespective of recruitment time after stroke onset; further, direct effects on smooth muscle would not explain apparent effects seen with less dependency, disability, cognitive impairment and mood disturbance, and improved quality of life [19, 21, 22]. Moreover, in the absence of direct measures of oesophageal physiology such as a barium swallow or manometry, it is not possible to say that oesophageal function was altered by GTN. Indeed, oesophageal relaxation might promote gastro-oesophageal reflux and the development of aspiration pneumonia; in reality, there was no evidence for this across the main trial [19] and a tendency to less pneumonia was seen in those treated early with GTN. As a result, the effect of GTN on feeding route is unlikely to be specific to swallowing.

The strengths of this study are its large size with data coming from a high fidelity trial that recruited more than 4000 patients from 5 continents and 23 countries. Data on feeding route at baseline were complete, and the findings consistent across outcomes. Hence, the results are likely to exhibit both internal and external validity. Nevertheless, several caveats need to be made. First, dysphagia was not routinely diagnosed using techniques such as videofluoroscopy or fibreoptic endoscopy, and clinical decisions on how to feed were based on local guideline-based practice that will have varied considerably across the 173 recruiting sites. As a result, we used route of feeding as a proxy for presumed or diagnosed dysphagia. One common model of care will have consisted of nurses performing a water-based screening test [25]; if swallowing was unsafe, they will have put the patient ‘nil by mouth’, and referred patients on to speech and language therapists for formal swallowing assessment and dieticians for provision of nutrition. Equally, some patients (almost 10% here) received no fluids or feeding over the first week. Although reasons were not collected, some physicians believe that the resulting dehydrating will reduce the development of cerebral oedema in patients with severe stroke; additionally, this may have reflected placing the patient on a care of the dying pathway. Although conceivable in a single-blind trial, it seems unlikely that any of these decisions will have been determined on the basis on randomised ENOS treatments.

Second, the feeding route scale used here is novel and not validated although it was defined prospectively and collected from the start of the trial in 2001 [17]; further, it is easy to assess clinically and its components exhibit face, content and construct validity. A criticism of the use of this scale at baseline is inclusion of PEG-feeding since this is most likely to represent a PEG from before the index stroke as acute PEG insertion within 48 h of stroke onset is not common practice. Third, ENOS mostly included patients with anterior circulation strokes (as is typical for most acute stroke trials) and so those with posterior strokes were underrepresented. Since there are differences in the role of brain regions in controlling swallowing, especially between hemispheres and brain stem, the results seen here may not be representative for posterior circulation strokes. Fourth, although information on the treatment of dysphagia during admission was not collected, more patients with non-oral feeding were seen by a speech and language therapist; this is most likely to have been for swallowing rather than speech problems. Fifth, some patients may have had pre-existing dysphagia, either due to a previous stroke or for another reason, and this information was not collected; 14.8% of patients reported a history of previous stroke and about half of these may have had this complicated by dysphagia, at least during the early phase of recovery. Previous dysphagia would then have made it less likely that patients would recover from the index swallowing problems. Sixth, data on pneumonia and chest infection came from serious adverse event reports and definitions were not operationalised; hence, the number of events will probably have been underestimated. Although investigator reporting of RTI may have been biased by knowledge of treatment assignment, it is unlikely that this would explain the magnitude of effects seen here. Last, information on other dysphagia-related outcomes such as malnutrition, body weight or albumin levels were not collected in the trial.

In summary, the route of feeding was abnormal in a significant minority of patients with acute stroke, with many of these recovering over the first week; non-oral feeding was associated with poor outcome. Trials of potential treatments for post-stroke dysphagia are urgently needed. The potential benefit of GTN on feeding route is being tested as a secondary outcome in the ongoing phase III RIGHT-2 trial of GTN given in the ultra-acute phase after stroke (http://​right-2.​ac.​uk). The route of feeding scale used here is novel and needs further assessment but is pragmatic and uses readily available information so may prove useful in the future.